0000000000611977

AUTHOR

G Sterrantino

showing 2 related works from this author

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.

2012

Introduction: This study aimed at defining protease (PR) resistance mutations associated with darunavir (DRV) failure and PR resistance evolution at DRV failure in a large database of treatment-experienced human immunodeficiency virus (HIV) patients. Results: Overall, 1,104 patients were included: 118 (10.7%) failed at a median observation time of 16 months. The mean number of PR mutations at baseline was 2.7, but it was higher in patients who subsequently failed DRV. In addition, the number of PR mutations increased at failure. The increase in the mean number of mutations was completely related to mutations considered to be associated with DRV resistance following the indications of the ma…

MaleTime FactorsCross-sectional studyHuman immunodeficiency virus (HIV)Drug ResistanceHIV InfectionsDrug resistancemedicine.disease_causeCohort StudiesAntiretroviral Therapy Highly ActiveRitonavir-boosted darunavirGenotypeHIV InfectionTreatment FailureViralGenotypic resistanceDarunavirSulfonamidesGeneral MedicineMiddle AgedVirological failureInfectious DiseasesFemaleHumanmedicine.drugAdultMicrobiology (medical)Logistic ModelTime FactorGenotypeAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVESulfonamideDrug Resistance ViralmedicineHumansHighly ActiveDarunavir; Genotypic resistance; Protease inhibitors; Ritonavir-boosted darunavir; Adult; Antiretroviral Therapy Highly Active; Cohort Studies; Cross-Sectional Studies; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Mutation; Sulfonamides; Time Factors; Treatment Failure; Drug Resistance Viral; Microbiology (medical); Infectious DiseasesHIV Protease InhibitorDarunavirCross-Sectional Studiebusiness.industryHIV Protease InhibitorsProtease inhibitorsAntiretroviral therapyVirologyCross-Sectional StudiesLogistic ModelsProtease inhibitorMutationGenotypic resistanceHIV-1Cohort Studiebusiness
researchProduct

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir i…

2013

Objectives: To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients. Patients and methods: A retrospective, longitudinal, multicentre analysis of adult patients enrolled in the Antiretroviral Resistance Cohort Analysis (ARCA), a national prospective observational cohort of HIV-1-infected patients followed up at more than 100 clinical and laboratory units in Italy. Patients eligible were those starting first-line antiretroviral therapy between 1 June 2004 and 15 April 2011 and who were followed up for at least 6 months. The primary endpoint was durability, define…

CyclopropanesTime FactorsPyridinesPyridineDrug ResistanceLopinavir/ritonavirLongitudinal StudieHIV InfectionsPharmacologyAntiviral therapyDeoxycytidineLopinavirCohort Studieschemistry.chemical_compoundimmune system diseasesRetrospective StudieOrganophosphonateMedicineEmtricitabineHIV InfectionPharmacology (medical)ViralLongitudinal StudiesProspective StudiesProspective cohort studyvirus diseasesLopinavirInfectious DiseasesAnti-Retroviral AgentsItalyAlkynesCombinationOligopeptideHIV/AIDSDrug Therapy CombinationOligopeptidesmedicine.drugHumanMicrobiology (medical)Benzoxazinemedicine.medical_specialtyEfavirenzTime Factorantiretroviral therapyAtazanavir SulfateOrganophosphonatesfirst-line therapy tenofovir emtricitabine atazanavir/ritonavirSettore MED/17 - MALATTIE INFETTIVEEmtricitabineDurabilityDrug TherapyInternal medicineDrug Resistance ViralDrug utilizationHumansAntiviral therapy; Drug utilization; Durability; HIV/AIDS; Tenofovir/emtricitabine; Adenine; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Deoxycytidine; Drug Resistance Viral; Drug Therapy Combination; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Time Factors; Pharmacology; Pharmacology (medical); Infectious DiseasesTenofovirRetrospective StudiesAntiviral therapy; Drug utilization; Durability; HIV/AIDS; Tenofovir/emtricitabine; Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Deoxycytidine; Drug Resistance Viral; Drug Therapy Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time FactorsPharmacologyRitonavirbusiness.industryAdenineAtazanavirBenzoxazinesRegimenProspective StudiechemistryHIV-1RitonavirAnti-Retroviral AgentCohort StudieTenofovir/emtricitabinebusiness
researchProduct